The present study will be a randomized controlled study in which 500 treatment-naive HIV patients will be randomized 1:1 to Efaviren 400mg v.s. 600mg combined with lamivudine and tenofovir. The whole cohort will be followed for two years. Efficacy and safety of each regimen will be evaluated throughout the study.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from Baseline Virological measurements at 12 weeks
Timeframe: 12 weeks
Change from Baseline Virological measurements at 24 weeks
Timeframe: 24 weeks
Change from Baseline Virological measurements at 48 weeks
Timeframe: 48 weeks
Change from Baseline Virological measurements at 72 weeks
Timeframe: 72 weeks
Change from Baseline Virological measurements at 96 weeks
Timeframe: 96 weeks
Change from Baseline Immunological measurements at 12 weeks
Timeframe: 12 weeks
Change from Baseline Immunological measurements at 24 weeks
Timeframe: 24 weeks
Change from Baseline Immunological measurements at 48 weeks
Timeframe: 48 weeks
Change from Baseline Immunological measurements at 72 weeks
Timeframe: 72 weeks
Change from Baseline Immunological measurements at 96 weeks
Timeframe: 96 weeks